Events and news

Home > Blog > Pharmacovigilance

Risk Management Plan: GVP Module V

European Medicines Agency published Module V of Good Vigilance Practices in 2012 and it was later revised in April 2014. The main objective of this module is to harmonize the development of the Risk Management Plan and its use in the European framework.
A Risk Management Plan is a mandatory report, required by the EMA for all Marketing Authorization Applications and it may be required in any moment during product life-cycle. It is a very complex report that characterizes the safety profile of any medicine, it is an accurate planification of all pharmacovigilance activities, it collects all implemented and planned measures to minimize and mitigate risks and eventually, it evaluates the efectiveness of all these measures.
The proposal of the development of a RMP includes:
• To early identify any risk from all existing information
• To identify areas where there is a lack of information
• To determine future research procedures to identify or characterize risks in a scientific-based approach
• To assure that pharmacovigilance activities start before Marketing Authorization Application and continue during the life-cycle

GVP Module

EMA established a fixed structure that must be followed to develop RMPs that contains defined parts:
I. General Overview of the medicine
II. Safety Specification: It covers all important identified risks, important potential risks, missing information and gaps that must be taken into account for further information
III. Pharmacovigilance plan: to early identify and/or characterize any potential risk
IV. Plan for post-authorisation efficacy studies: Summary figure of planned studies with the agenda and protocols of all drafts should be submitted with the RMP
V. Risk Minimization Measures (Including all activities to assess effectiveness of these measures)
VI. Summary of RMP
VII. Annex
In Azierta we have a team of drug safety experts able to prepare any kind of safety report, helping companies to ensure safety and maintain a good risk-benefit ratio of their medicinal products.
Check out our Risk Management Plan presentation on Slideshare or visit our safety reports website for more details and feel free to contact us, we will be pleased to help you.


Related posts

Development Update Safety Report

According to ICH guideline E2F (Step 5) on Development Safety Update Reports (DSURs) already implemented since 2011, companies...

Read more

Development Safety Update Report (DSUR)

In September 2010, the International Conference Harmonisation developed the ICH E2F Guideline for the Development Safety...

Read more

Líderes del sector farma & salud

100 professionals

Over 100 professionals

500 clients

Over 500 clients

9 year experience

9 years of experience


Leading innovation

Client oriented

100% client oriented

We are at your complete disposal for any inquiry

Schedule appointment

Schedule a video call with our field experts




Madrid (HQ)

Vía de las Dos Castillas 33, Edificio 7 - 28224 Pozuelo de Alarcón (Madrid)

912 77 10 76




Ctra. de l'Hospitalet, 147, Edificio Roma - 08940 Barcelona

912 77 10 76




Calle 25 nº 68-35

(+57) 3103498206




Avenida da Liberdade, 10

(+34) 91 277 10 76




Bastioni di Porta Nuova, 21 - 20121 Milan

(+34) 91 277 10 76




54 rue de Londres - 75008 Paris

(+33) 180 209 978


We use "cookies" to improve your experience on our site. Cookies enable us to tailor messages and display ads to your interests. They also help us understand how our site is being used. By continuing to use our site you consent to use our cookies.